Pharmacokinetics

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibodies and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, payload … Read more

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibody drugs and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, … Read more

How Do Antibody-Drug Conjugates (ADCs) Accurately Hit Their Targets? In-Depth Analysis of the Latest Analytical Techniques and Core Pharmacokinetic Modeling Strategies

by

On the battlefield of precise cancer treatment, Antibody-Drug Conjugates (ADCs) act like a “biological missile,” leveraging their precise targeting capabilities and powerful lethality to become a cornerstone of tumor therapy. However, the journey of this “missile” within the body is exceptionally complex, and accurately tracking it and predicting its behavior has become the key to … Read more

Opportunities for Newcomers in ADC Drugs Amid Challenges!

by
Opportunities for Newcomers in ADC Drugs Amid Challenges!

Click to follow Xiaobai Learning MedicineIntroduction: Since the approval of the first ADC drug Mylotarg® (Gemtuzumab Ozogamicin) in 2000, the number of ADC drugs has exploded, with 14 types of ADCs approved for market, and hundreds of ADC drugs undergoing clinical trials for various tumor indications. While ADCs are effective, their clinical development and application … Read more

Key Considerations in ADC Design Based on Pharmacokinetics

by
Key Considerations in ADC Design Based on Pharmacokinetics

Please click the “Bio New Thinking” above to follow for more exciting content! Introduction With the continuous improvement of biopharmaceutical research and clinical research levels, the research and application of Antibody-Drug Conjugates (ADCs) have been increasing. ADCs are mainly composed of antibodies, linkers, and small molecule toxins, combining high targeting specificity with high cytotoxicity. However, … Read more

Key Points and Challenges in PK/PD Studies of ADC Drugs

by
Key Points and Challenges in PK/PD Studies of ADC Drugs

Click the blue text above to follow us IntroductionAntibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule toxins. While they possess the advantages of high targeting ability and high cytotoxicity, their structural diversity and complexity, as well as the low levels of small molecule toxins released in the circulatory system, present numerous challenges for … Read more

Fundamentals of Clinical Pharmacology of ADCs

by
Fundamentals of Clinical Pharmacology of ADCs

Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more

Fundamentals of Clinical Pharmacology of ADCs

by

Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens to small-molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute myeloid leukemia, dozens … Read more

Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

by
Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Lepu Biopharma’s Class 1 new drug MRG007 has been approved for clinical trials,aiming to develop treatments for locally advanced or metastatic solid tumors. Public information indicates that this is aCDH17-targeted antibody-drug conjugate (ADC),formed by conjugating a novel humanized … Read more

Introduction to ADC: A Brief Overview of Clinical Pharmacology

by
Introduction to ADC: A Brief Overview of Clinical Pharmacology

Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more